Key Points
- Amy Burroughs, CEO of Terns Pharmaceuticals, sold 68,749 shares on Jan 15 at an average of $37.07 for a total of $2,548,525.43, trimming her stake by 19.22% to 288,976 shares valued at about $10.71M.
- Terns (NASDAQ:TERN) opened at $36.60 with a 50‑day/200‑day SMA of $34.51/$16.80, a market cap of ~$3.30B, and a 52‑week range of $1.87–$48.26.
- Analysts are broadly positive—consensus rating "Moderate Buy" with an average target of $55.56 (1 Strong Buy, 11 Buy, 1 Sell)—and the company recently reported a quarterly loss of ($0.27) EPS, slightly beating estimates, while FY expectations remain negative (~-1.19 EPS).
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 68,749 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $37.07, for a total value of $2,548,525.43. Following the sale, the chief executive officer owned 288,976 shares of the company's stock, valued at $10,712,340.32. This trade represents a 19.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Terns Pharmaceuticals Stock Down 1.0%
Shares of NASDAQ TERN opened at $36.60 on Friday. The stock's fifty day simple moving average is $34.51 and its 200 day simple moving average is $16.80. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of -35.53 and a beta of -0.28. Terns Pharmaceuticals, Inc. has a 52-week low of $1.87 and a 52-week high of $48.26.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. As a group, analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its position in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company's stock worth $35,000 after buying an additional 770 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at approximately $80,000. Polymer Capital Management US LLC acquired a new stake in Terns Pharmaceuticals in the 3rd quarter worth approximately $76,000. Tema Etfs LLC bought a new stake in Terns Pharmaceuticals during the fourth quarter worth approximately $414,000. Finally, Engineers Gate Manager LP bought a new position in shares of Terns Pharmaceuticals in the second quarter valued at approximately $41,000. Institutional investors own 98.26% of the company's stock.
Wall Street Analyst Weigh In
TERN has been the topic of several research analyst reports. UBS Group upgraded shares of Terns Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, December 4th. Citigroup reissued an "outperform" rating on shares of Terns Pharmaceuticals in a research report on Wednesday, November 26th. Mizuho raised their price objective on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 9th. BMO Capital Markets raised their price target on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, December 9th. Finally, Citizens Jmp increased their target price on shares of Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a "market outperform" rating in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.56.
Get Our Latest Stock Analysis on TERN
About Terns Pharmaceuticals
(
Get Free Report)
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
